A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
A Phase II, Randomized, Open Label, Multi-center Design Study of Toripalimab Given Before and After Concurrent Chemoradiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Suspended
combination arm delevelped significant poor prognosis
This PHASE2 trial investigates Esophageal Squamous Cell Carcinoma and is currently suspended. Shanghai Junshi Bioscience Co., Ltd. leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Suspended PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Suspended PHASE2
-
Mar 2021 — Oct 2021 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Oct 2019 — Jan 2021 [monthly]
Recruiting PHASE2
First recorded
Sep 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Junshi Bioscience Co., Ltd.
- Zhejiang Cancer Hospital
For direct contact, visit the study record on ClinicalTrials.gov .